Seminars in Oncology
Volume 31, Issue 5 , Pages 618-634 , October 2004

Anaplastic astrocytoma: Diagnosis, prognosis, and management

  • Siew Ju See

      Affiliations

    • Department of Neurology, National Neuroscience Institute, Singapore General Hospital, Singapore.
    • ,
  • Mark R. Gilbert

      Affiliations

    • Department of Neuro-oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
    • Corresponding Author InformationAddress reprint requests to Mark R. Gilbert, MD, Department of Neuro-oncology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030.

References 

  1. CBTRUS . Statistical Report (Primary Brain Tumors in the United States, 1995–1999) . Chicago, IL: Central Brain Tumor Registry of the United States; 2002;
  2. Kleihues PDR , Coons SW , Burger PC . Astrocytic tumors . In:  Kleihues PCW editors. World Health Organization Classification of Tumors (Pathology and Genetics of Tumors of the Nervous System) . Lyon, France: IARC Press; 2000;p. 27–28
  3. Scott JN , Brasher PM , Sevick RJ , et al.   How often are nonenhancing supratentorial gliomas malignant? A population study . Neurology . 2002;59:947–949
  4. Ginsberg LE , Fuller GN , Hashmi M , et al.   The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults (Histopathological evaluation of a series) . Surg Neurol . 1998;49:436–440
  5. Law M , Meltzer DE , Cha S . Spectroscopic magnetic resonance imaging of a tumefactive demyelinating lesion . Neuroradiology . 2002;44:986–989
  6. Krouwer HG , Kim TA , Rand SD , et al.   Single-voxel proton MR spectroscopy of nonneoplastic brain lesions suggestive of a neoplasm . Am J Neuroradiol . 1998;19:1695–1703
  7. Burtscher IM , Skagerberg G , Geijer B , et al.   Proton MR spectroscopy and preoperative diagnostic accuracy (An evaluation of intracranial mass lesions characterized by stereotactic biopsy findings) . Am J Neuroradiol . 2000;21:84–93
  8. Law M , Cha S , Knopp EA , et al.   High-grade gliomas and solitary metastases (Differentiation by using perfusion and proton spectroscopic MR imaging) . Radiology . 2002;222:715–721
  9. Ishimaru H , Morikawa M , Iwanaga S , et al.   Differentiation between high-grade glioma and metastatic brain tumor using single-voxel proton MR spectroscopy . Eur Radiol . 2001;11:1784–1791
  10. Dowling C , Bollen AW , Noworolski SM , et al.   Preoperative proton MR spectroscopic imaging of brain tumors (Correlation with histopathologic analysis of resection specimens) . Am J Neuroradiol . 2001;22:604–612
  11. Poptani H , Gupta RK , Roy R , et al.   Characterization of intracranial mass lesions with in vivo proton MR spectroscopy . Am J Neuroradiol . 1995;16:1593–1603
  12. Herminghaus S , Dierks T , Pilatus U , et al.   Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data . J Neurosurg . 2003;98:74–81
  13. Roelcke U , Leenders KL . Positron emission tomography in patients with primary CNS lymphomas . J Neurooncol . 1999;43:231–236
  14. Di Chiro RD , Brooks RA , Sokoloff L , et al.   Glucose utilization of cerebral gliomas measured by 18F fluorodeoxyglucose and positron emission tomography . Neurology . 1982;32:1323–1329
  15. Roelcke U , Leenders KL . PET in neuro-oncology . J Cancer Res Clin Oncol . 2001;127:2–8
  16. Wienhard K , Herholz K , Coenen HH , et al.   Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine . J Nucl Med . 1991;32:1338–1346
  17. Ishiwata K , Kubota K , Murakami M , et al.   Re-evaluation of amino acid PET studies (Can the protein synthesis rates in brain and tumor tissues be measured in vivo?) . J Nucl Med . 1993;34:1936–1943
  18. Schmidt D , Gottwald U , Langen KJ , et al.   3-[123I]Iodo-alpha-methyl-L-tyrosine uptake in cerebral gliomas (Relationship to histological grading and prognosis) . Eur J Nucl Med . 2001;28:855–861
  19. Kuwert T , Morgenroth C , Woesler B , et al.   Uptake of iodine-123-alpha-methyl tyrosine by gliomas and non-neoplastic brain lesions . Eur J Nucl Med . 1996;23:1345–1353
  20. Woesler B , Kuwert T , Morgenroth C , et al.   Non-invasive grading of primary brain tumours (Results of a comparative study between SPET with 123I-alpha-methyl tyrosine and PET with 18F-deoxyglucose) . Eur J Nucl Med . 1997;24:428–434
  21. Jackson RJ , Fuller GN , Abi-Said D , et al.   Limitations of stereotactic biopsy in the initial management of gliomas . Neurooncology . 2001;3:193–200
  22. McGirt MJ , Villavicencio AT , Bulsara KR , et al.   MRI-guided stereotactic biopsy in the diagnosis of glioma (Comparison of biopsy and surgical resection specimen) . Surg Neurol . 2003;59:277–281
  23. Son BC , Kim MC , Choi BG , et al.   Proton magnetic resonance chemical shift imaging (1H CSI)-directed stereotactic biopsy . Acta Neurochir (Wien) . 2001;143:45–49
  24. Pirotte B , Goldman S , Bidaut LM , et al.   Use of positron emission tomography (PET) in stereotactic conditions for brain biopsy . Acta Neurochir (Wien) . 1995;134:79–82
  25. Levivier M , Goldman S , Pirotte B , et al.   Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F] fluorodeoxyglucose . J Neurosurg . 1995;82:445–452
  26. Herholz K , Pietrzyk U , Voges J , et al.   Correlation of glucose consumption and tumor cell density in astrocytomas (A stereotactic PET study) . J Neurosurg . 1993;79:853–858
  27. Goldman S , Levivier M , Pirotte B , et al.   Regional glucose metabolism and histopathology of gliomas (A study based on positron emission tomography-guided stereotactic biopsy) . Cancer . 1996;78:1098–1106
  28. Yung WK , Prados MD , Yaya-Tur R , et al.   Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse (Temodal Brain Tumor Group) . J Clin Oncol . 1999;17:2762–2771
  29. Smith JS , Perry A , Borell TJ , et al.   Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas . J Clin Oncol . 2000;18:636–645
  30. Burger PC , Vogel FS , Green SB , et al.   Glioblastoma multiforme and anaplastic astrocytoma (Pathologic criteria and prognostic implications) . Cancer . 1985;56:1106–1111
  31. Kim TS , Halliday AL , Hedley-Whyte ET , et al.   Correlates of survival and the Daumas-Duport grading system for astrocytomas . J Neurosurg . 1991;74:27–37
  32. Daumas-Duport C , Scheithauer B , O’Fallon J , et al.   Grading of astrocytomas (A simple and reproducible method) . Cancer . 1988;62:2152–2165
  33. Barker FG , Davis RL , Chang SM , et al.   Necrosis as a prognostic factor in glioblastoma multiforme . Cancer . 1996;77:1161–1166
  34. Perry A , Jenkins RB , O’Fallon JR , et al.   Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors (An analysis of DNA content (ploidy), cellular proliferation, and p53 expression) . Cancer . 1999;86:672–683
  35. Tortosa A , Vinolas N , Villa S , et al.   Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas . Cancer . 2003;97:1063–1071
  36. Korshunov A , Golanov A , Sycheva R . Immunohistochemical markers for prognosis of anaplastic astrocytomas . J Neurooncol . 2002;58:203–215
  37. Ralte AM , Sharma MC , Karak AK , et al.   Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors . Pathol Oncol Res . 2001;7:267–278
  38. Ohgaki H , Schauble B , zur Hausen A , et al.   Genetic alterations associated with the evolution and progression of astrocytic brain tumours . Virchows Arch . 1995;427:113–118
  39. Watanabe K , Sato K , Biernat W , et al.   Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies . Clin Cancer Res . 1997;3:523–530
  40. Smith JS , Tachibana I , Passe SM , et al.   PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme . J Natl Cancer Inst . 2001;93:1246–1256
  41. Nakamura M , Konishi N , Tsunoda S , et al.   Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma . Cancer . 1997;80:242–249
  42. Balesaria S , Brock C , Bower M , et al.   Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas . Br J Cancer . 1999;81:1371–1377
  43. Rasheed A , Herndon JE , Stenzel TT , et al.   Molecular markers of prognosis in astrocytic tumors . Cancer . 2002;94:2688–2697
  44. Cairncross JG , Ueki K , Zlatescu MC , et al.   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas . J Natl Cancer Inst . 1998;90:1473–1479
  45. Ino Y , Zlatescu MC , Sasaki H , et al.   Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss . J Neurosurg . 2000;92:983–990
  46. Smith JS , Alderete B , Minn Y , et al.   Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype . Oncogene . 1999;18:4144–4152
  47. Kumar AJ , Leeds NE , Fuller GN , et al.   Malignant gliomas (MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment) . Radiology . 2000;217:377–384
  48. Di Chiro G , Oldfield E , Wright DC , et al.   Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors (PET and neuropathologic studies) . Am J Roentgenol . 1988;150:189–197
  49. Langleben DD , Segall GM . PET in differentiation of recurrent brain tumor from radiation injury . J Nucl Med . 2000;41:1861–1867
  50. Chao ST , Suh JH , Raja S , et al.   The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery . Int J Cancer . 2001;96:191–197
  51. Ricci PE , Karis JP , Heiserman JE , et al.   Differentiating recurrent tumor from radiation necrosis (Time for re-evaluation of positron emission tomography?) . Am J Neuroradiol . 1998;19:407–413
  52. Thompson TP , Lunsford LD , Kondziolka D . Distinguishing recurrent tumor and radiation necrosis with positron emission tomography versus stereotactic biopsy . Stereotact Funct Neurosurg . 1999;73:9–14
  53. Preul MC , Leblanc R , Caramanos Z , et al.   Magnetic resonance spectroscopy guided brain tumor resection (Differentiation between recurrent glioma and radiation change in two diagnostically difficult cases) . Can J Neurol Sci . 1998;25:13–22
  54. Rabinov JD , Lee PL , Barker FG , et al.   In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects (Initial experience) . Radiology . 2002;225:871–879
  55. Rock JP , Hearshen D , Scarpace L , et al.   Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis . Neurosurgery . 2002;51:912–919
  56. Albert FK , Forsting M , Sartor K , et al.   Early postoperative magnetic resonance imaging after resection of malignant glioma (Objective evaluation of residual tumor and its influence on regrowth and prognosis) . Neurosurgery . 1994;34:45–60
  57. Hess KR . Extent of resection as a prognostic variable in the treatment of gliomas . J Neurooncol . 1999;42:227–231
  58. Vuorinen V , Hinkka S , Farkkila M , et al.   Debulking or biopsy of malignant glioma in elderly people—A randomised study . Acta Neurochir (Wien) . 2003;145:5–10
  59. Laws ER , Shaffrey ME , Morris A , et al.   Surgical management of intracranial gliomas—Does radical resection improve outcome? . Acta Neurochir . 2003;85(suppl):47–53
  60. Cohen ZR , Shi W , Weinberg JS . Surgical resection of anaplastic astrocytoma (prognostic factors and outcome) . Neurooncology . 2002;4:367; (abstr)
  61. Walker MD , Green SB , Byar DP , et al.   Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery . N Engl J Med . 1980;303:1323–1329
  62. Walker MD , Alexander E , Hunt WE , et al.   Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas (A cooperative clinical trial) . J Neurosurg . 1978;49:333–343
  63. Kristiansen K , Hagen S , Kollevold T , et al.   Combined modality therapy of operated astrocytomas grade III and IV (Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the Scandinavian Glioblastoma Study Group) . Cancer . 1981;47:649–652
  64. Hochberg FH , Pruitt A . Assumptions in the radiotherapy of glioblastoma . Neurology . 1980;30:907–911
  65. Liang BC , Thornton AF , Sandler HM , et al.   Malignant astrocytomas (focal tumor recurrence after focal external beam radiation therapy) . J Neurosurg . 1991;75:559–563
  66. Gaspar LE , Fisher BJ , Macdonald DR , et al.   Supratentorial malignant glioma (Patterns of recurrence and implications for external beam local treatment) . Int J Radiat Oncol Biol Phys . 1992;24:55–57
  67. Medical Research Council . Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma (A Medical Research Council trial) . J Clin Oncol . 2001;19:509–518
  68. Scott CB , Curran WJ , Yung WKA . Long term results of RTOG 9006 (A randomized trial of hyperfractionated radiotherpay (RT) to 72.0 Gy and carmustine vs standard RT & carmustine for malignant glioma patients with emphasis on anaplastic astrocytoma (AA) patients) . Proc Am Soc Clin Oncol . 1998;17:401a; (abstr)
  69. Prados MD , Wara WM , Sneed PK , et al.   Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme . Int J Radiat Oncol Biol Phys . 2001;49:71–77
  70. Levin VA , Yung WK , Bruner J , et al.   Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas . Int J Radiat Oncol Biol Phys . 2002;53:58–66
  71. Bleehen NM , Wiltshire CR , Plowman PN , et al.   A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma . Br J Cancer . 1981;43:436–442
  72. Levin VA , Wilson CB , Davis R , et al.   A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas . J Neurosurg . 1979;51:526–532
  73. Goffman TE , Dachowski LJ , Bobo H , et al.   Long-term follow-up on National Cancer Institute phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation . J Clin Oncol . 1992;10:264–268
  74. Nelson DF , Diener-West M , Weinstein AS , et al.   A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery (Final report of an RTOG study) . Int J Radiat Oncol Biol Phys . 1986;12:1793–1800
  75. Prados MD , Scott C , Sandler H , et al.   A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma (A preliminary report of RTOG 9404) . Int J Radiat Oncol Biol Phys . 1999;45:1109–1115
  76. Peterson K , Harsh GT , Fisher PG , et al.   Daily low-dose carboplatin as a radiation sensitizer for newly diagnosed malignant glioma . J Neurooncol . 2001;53:27–32
  77. Jeremic B , Shibamoto Y , Grujicic D , et al.   Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma (Long-term results of a phase II study) . J Neurooncol . 2001;51:133–141
  78. Pfeffer LM , Dinarello CA , Herberman RB , et al.   Biological properties of recombinant alpha-interferons (40th anniversary of the discovery of interferons) . Cancer Res . 1998;58:2489–2499
  79. Dillman RO , Shea WM , Tai DF , et al.   Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma . Neurooncology . 2001;3:35–41
  80. Buckner JC , Schomberg PJ , McGinnis WL , et al.   A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma . Cancer . 2001;92:420–433
  81. Emami B , Lyman J , Brown A , et al.   Tolerance of normal tissue to therapeutic irradiation . Int J Radiat Oncol Biol Phys . 1991;21:109–122
  82. Florell RC , Macdonald DR , Irish WD , et al.   Selection bias, survival, and brachytherapy for glioma . J Neurosurg . 1992;76:179–183
  83. Selker RG , Shapiro WR , Burger P , et al.   The Brain Tumor Cooperative Group NIH Trial 87–01 (A randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine) . Neurosurgery . 2002;51:343–355
  84. Kondziolka D , Flickinger JC , Bissonette DJ , et al.   Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms . Neurosurgery . 1997;41:776–783
  85. Lucas GL , Luxton G , Cohen D , et al.   Treatment results of stereotactic interstitial brachytherapy for primary and metastatic brain tumors . Int J Radiat Oncol Biol Phys . 1991;21:715–721
  86. Loeffler JS , Alexander E , Shea WM , et al.   Radiosurgery as part of the initial management of patients with malignant gliomas . J Clin Oncol . 1992;10:1379–1385
  87. Curran WJ , Scott CB , Weinstein AS , et al.   Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine (A report of Radiation Therapy Oncology Group 83–02) . J Clin Oncol . 1993;11:857–862
  88. Souhami L , Scott C , Brachman D , et al.   Randomized prospective comparison of stereotactic radiosurgery (SRS) followed y conventional radiotherapy (RT) with BCNU to RT with BCNU alone for selected patients with supratentorial glioblastoma multiforme (GBM) (Report of RTOG 93–05 protocol) . Int J Radiat Oncol Biol Phys . 2002;54:94–95
  89. Chamberlain MC , Barba D , Kormanik P , et al.   Stereotactic radiosurgery for recurrent gliomas . Cancer . 1994;74:1342–1347
  90. Laing RW , Warrington AP , Graham J , et al.   Efficacy and toxicity of fractionated stereotactic radiotherapy in the treatment of recurrent gliomas (phase I/II study) . Radiother Oncol . 1993;27:22–29
  91. Hall WA , Djalilian HR , Sperduto PW , et al.   Stereotactic radiosurgery for recurrent malignant gliomas . J Clin Oncol . 1995;13:1642–1648
  92. Shepherd SF , Laing RW , Cosgrove VP , et al.   Hypofractionated stereotactic radiotherapy in the management of recurrent glioma . Int J Radiat Oncol Biol Phys . 1997;37:393–398
  93. Wen PY , Alexander E , Black PM , et al.   Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas . Cancer . 1994;73:3029–3036
  94. Bernstein M , Laperriere N , Glen J , et al.   Brachytherapy for recurrent malignant astrocytoma . Int J Radiat Oncol Biol Phys . 1994;30:1213–1217
  95. Fine HA , Dear KB , Loeffler JS , et al.   Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults . Cancer . 1993;71:2585–2597
  96. Stewart LA . Chemotherapy in adult high-grade glioma (A systematic review and meta-analysis of individual patient data from 12 randomised trials) . Lancet . 2002;359:1011–1018
  97. :279–284, 1988 Nelson DF , Diener-West M , Horton J . Combined modality approach to treatment of malignant gliomas—Re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up (A joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group) . NCI Monogr X . 1988;279–284
  98. Levin VA , Silver P , Hannigan J , et al.   Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas (NCOG 6G61 final report) . Int J Radiat Oncol Biol Phys . 1990;18:321–324
  99. Prados MD , Scott C , Curran WJ , et al.   Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma (A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy) . J Clin Oncol . 1999;17:3389–3395
  100. Levin VA , Hess KR , Choucair A , et al.   Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas . Clin Cancer Res . 2003;9:981–990
  101. Prados MD , Larson DA , Lamborn K , et al.   Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors . Int J Radiat Oncol Biol Phys . 1998;40:57–63
  102. Wong ET , Hess KR , Gleason MJ , et al.   Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials . J Clin Oncol . 1999;17:2572; (abstr)
  103. O’Reilly SM , Newlands ES , Glaser MG , et al.   Temozolomide (A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours) . Eur J Cancer . 1993;29A:940–942
  104. Jeremic B , Grujicic D , Jevremovic S , et al.   Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma (A phase II study) . J Clin Oncol . 1992;10:1074–1077
  105. Kyritsis AP , Yung WK , Jaeckle KA , et al.   Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas . Neurosurgery . 1996;39:921–926
  106. Friedman HS , Petros WP , Friedman AH , et al.   Irinotecan therapy in adults with recurrent or progressive malignant glioma . J Clin Oncol . 1999;17:1516–1525
  107. Quinn JA , Pluda J , Dolan ME , et al.   Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma . J Clin Oncol . 2002;20:2277–2283
  108. Quinn JWH , Brem J , Rich D . Phase I trial of temozolomide plus O6-benzylguanine in the treatment of patients with recurrent or progressive cerebral anaplastic gliomas . Proc Am Soc Clin Oncol . 2003;22:103; (abstr)
  109. Chang SM , Schiff KD , Fine H , et al.   Phase II study of neoadjuvant BCNU and temozolomide for newly diagnosed anaplastic glioma . Proc Am Soc Clin Oncol . 2003;22:103; (abstr)
  110. Newlands ES , Foster T , Zaknoen S . Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas . Br J Cancer . 2003;89:248–251
  111. Jeremic B , Shibamoto Y , Grujicic D , et al.   Pre-irradiation carboplatin and etoposide and accelerated hyperfractionated radiation therapy in patients with high-grade astrocytomas (A phase II study) . Radiother Oncol . 1999;51:27–33
  112. Madajewicz S , Chowhan N , Tfayli A , et al.   Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy . Cancer . 2000;88:2350–2356
  113. Rao RD , Schomberg PJ , Dinapoli RP , et al.   A phase II trial of pre-irradiation chemotherapy with BCNU, cisplatin and oral etoposide combined with radiation therapy in hte treatment of grade 3 astrocytoma (anaplastic astrocytoma) . Neurooncology . 2002;4:374–375
  114. Gilbert MR , Friedman HS , Kuttesch JF , et al.   A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy . Neurooncology . 2002;4:261–267
  115. Aoki S , Terada H , Kosuda S , et al.   Supraophthalmic chemotherapy with long tapered catheter (distribution evaluated with intraarterial and intravenous Tc-99m HMPAO) . Radiology . 1993;188:347–350
  116. Saris SC , Blasberg RG , Carson RE , et al.   Intravascular streaming during carotid artery infusions (Demonstration in humans and reduction using diastole-phased pulsatile administration) . J Neurosurg . 1991;74:763–772
  117. Ashby LS , Shapiro WR . Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma (A phase II study) . J Neurooncol . 2001;51:67–86
  118. Doolittle ND , Miner ME , Hall WA , et al.   Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors . Cancer . 2000;88:637–647
  119. Vega F , Davila L , Chatellier G , et al.   Treatment of malignant gliomas with surgery, intraarterial chemotherapy with ACNU and radiation therapy . J Neurooncol . 1992;13:131–135
  120. Newton HB , Slivka MA , Stevens CL , et al.   Intra-arterial carboplatin and intravenous etoposide for the treatment of recurrent and progressive non-GBM gliomas . J Neurooncol . 2002;56:79–86
  121. Prados MD , Schold SJS , Fine HA , et al.   A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma . Neurooncology . 2003;5:96–9103
  122. Westphal M , Hilt DC , Bortey E , et al.   A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma . Neurooncology . 2003;5:79–88
  123. Brem H , Piantadosi S , Burger PC , et al.   Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas (The Polymer-brain Tumor Treatment Group) . Lancet . 1995;345:1008–1012
  124. Valtonen S , Timonen U , Toivanen P , et al.   Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas (A randomized double-blind study) . Neurosurgery . 1997;41:44–49
  125. Sheleg SV , Korotkevich EA , Zhavrid EA , et al.   Local chemotherapy with cisplatin-depot for glioblastoma multiforme . J Neurooncol . 2002;60:53–59
  126. Hassenbusch SJ , Nardone EM , Levin VA , et al.   Stereotactic injection of DTI-015 into recurrent malignant gliomas (Phase I/II trial) . Neoplasia . 2003;5:9–16
  127. Sawada T , Kato Y , Sakayori N , et al.   Expression of the multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors . Brain Tumor Pathol . 1999;16:23–27
  128. Thomas H , Coley HM . Overcoming multidrug resistance in cancer (An update on the clinical strategy of inhibiting p-glycoprotein) . Cancer Control . 2003;10:159–165
  129. Tremont-Lukats IW , Gilbert MR . Advances in molecular therapies in patients with brain tumors . Cancer Control . 2003;10:125–137
  130. Yung WK , Kyritsis AP , Gleason MJ , et al.   Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid . Clin Cancer Res . 1996;2:1931–1935
  131. Jaeckle KA , Hess KR , Yung WK , et al.   Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma (A North American Brain Tumor Consortium study) . J Clin Oncol . 2003;21:2305–2311
  132. Groves MD , Gilbert MR , Conrad C , et al.   A phase II study of temozolomide plus marimastat for recurrent anaplastic glioma (AG) . Neuro-oncology . 2002;4:369
  133. Fine HA , Figg WD , Jaeckle K , et al.   Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas . J Clin Oncol . 2000;18:708–715
  134. Chamberlain MC , Kormanik PA . Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas . Arch Neurol . 1999;56:703–708
  135. Brandes AA , Ermani M , Turazzi S , et al.   Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas (A phase II study) . J Clin Oncol . 1999;17:645–650
  136. Ringertz J . Grading of gliomas . Acta Pathol Microbiol Scand . 1950;27:51–64
  137. Kernohan JW , Sayre GP . Astrocytomas . In:  Sayre GP editors. Atlas of Tumor Pathology Section 10 Fascicles 35 and 37 Tumors of the Central Nervous System . Washington, DC: US Armed Forces Institute of Pathology; 1952;p. 22–42
  138. Ron IG , Gal O , Vishne TH , et al.   Long-term follow-up in managing anaplastic astrocytoma by multimodality approach with surgery followed by postoperative radiotherapy and PCV-chemotherapy (Phase II trial) . Am J Clin Oncol . 2002;25:296–302

PII: S0093-7754(04)00326-4

doi: 10.1053/j.seminoncol.2004.07.004

Seminars in Oncology
Volume 31, Issue 5 , Pages 618-634 , October 2004

Article Tools

* Image Usage & Resolution